Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 55, Issue 10, 2010, Pages 2712-2726

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Molecular interventions; Targeted therapy

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIGEN; AZATHIOPRINE; CD20 ANTIBODY; CERTOLIZUMAB PEGOL; CYTOCHROME P450 2D6; DNA VACCINE; ETANERCEPT; GOLIMUMAB; HLA DR ANTIGEN; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY CD3; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 10; RITUXIMAB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SYNTHETIC PEPTIDE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADENOVIRUS; ADOPTIVE TRANSFER; ALCOHOL LIVER DISEASE; ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELLULAR IMMUNITY; CHILL; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE MODEL; DNA IMMUNIZATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENTERITIS; FLU LIKE SYNDROME; GENE SILENCING; HEPATITIS C; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL PNEUMONIA; INTESTINE PERFORATION; LIVER FIBROSIS; LYMPHOCYTE DIFFERENTIATION; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; MYALGIA; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROMOTER REGION; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; VIRUS EXPRESSION; VIRUS HEPATITIS; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY;

ANIMALS; AUTOANTIGENS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; SIGNAL TRANSDUCTION;

EID: 77957893679     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1122-8     Document Type: Review

References (220)

1. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159-185.
2. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820-833.
3. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735-737.
4. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16:876-883.
5. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980;21:78-83.
6. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996; 110:848-857.
7. Floreani A, Niro G, Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051-1057.
8. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410-1414.
9. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol. 1993;18:15-23.
10. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997;127: 981-985.
11. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol. 2001;32:428-430.
12. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646-652.
13. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005;50:547-551.
14. Czaja AJ, Wolf AM, Summerskill WH. Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. Gastroenterology. 1979;77:629-633.
15. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161-167.
16. Czaja AJ, Freese DK. Practice guidelines of the American Association for the Study of Liver Diseases. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-497.
17. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269-291.
18. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;92:215-219.
19. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319-333.
20. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138-1145.
21. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622-627.
22. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.Gastroenterology. 1980;78: 518-523.
23. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroidtreated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med. 1981;304:5-9.
24. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685-689.
25. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890-897.
26. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23:116-123.
27. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006;43:S132-S144.
28. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113-128.
29. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008;14:3306-3312.
30. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 2002;6:825-850. ix.
31. Schalm SW, Summerskill WH, Go VL. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology. 1977;72:910-913.
32. Uribe M, Summerskill WH, Go VL. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin Pharmacokinet. 1982;7:452-459.
33. Uribe M, Go VL, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol. 1984;6:331-335.
34. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10(Suppl 2):81-90. discussion 91-82.
35. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol. 2000;109:16-22.
36. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol. 2001;2:78-82.
37. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30:358-363.
38. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
39. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91: 423-433.
40. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29:601-605.
41. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
42. Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol. 2008;2:23-34.
43. Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312:537-545.
44. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology. 2002; 35:7-13.
45. Wolfraim LA. Treating autoimmune diseases through restoration of antigen-specific immune tolerance. Arch Immunol Ther Exp (Warsz). 2006;54:1-13.
46. Myers LK, Rosloniec EF, Seyer JM, Stuart JM, Kang AH. A synthetic peptide analogue of a determinant of type II collagenprevents the onset of collagen-induced arthritis. J Immunol. 1993;150:4652-4658.
47. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci U S A. 1998;95:12528-12531.
48. Myers LK, Tang B, Rosloniec EF, et al. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol. 1998;161:3589-3595.
49. Hanson GJ. DR (MHC class II) ligands: an approach to rheumatoid arthritis therapeutics. Curr Pharm Des. 1998;4:397-402.
50. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol. 2000;61:640-650.
51. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340:1704-1714.
52. Fiocco U, Sfriso P, Oliviero F, et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev. 2008;8:76-82.
53. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104:276-284.
54. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;CD007277.
55. Bach MA, Bach JF. The use of monoclonal anti-T cell antibodies to study T cell imbalances in human diseases. Clin Exp Immunol. 1981;45:449-456.
56. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
57. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39: 1390-1397.
58. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-1472.
59. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000;118:655-660.
60. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006; 26:625-629.
61. Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology. 1998;27:1536-1543.
62. Guan Q, Ma Y, Hillman CL, et al. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine. 2009.
63. Wardrop RM III, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res. 1999;48: 106-119.
64. Nagler A, Pines M, Abadi U, et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology. 2000;31:641-648.
65. McCafferty AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol. 2003;21:639-644.
66. Hannon GJ. RNA interference. Nature. 2002;418:244-251.
67. Davidson BL. Hepatic diseases-hitting the target with inhibitory RNAs. N Engl J Med. 2003;349:2357-2359.
68. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature. 2004;431:371-378.
69. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9: 347-351.
70. Howell CD. Animal models of autoimmunity. Clin Liver Dis. 2002;6:775-783.
71. Christen U, Holdener M, Hintermann E. Animal models for autoimmune hepatitis. Autoimmun Rev. 2007;6:306-311.
72. Jaeckel E. Animal models of autoimmune hepatitis. Semin Liver Dis. 2002;22:325-338.
73. Peters MG. Animal models of autoimmune liver disease. Immunol Cell Biol. 2002;80:113-116.
74. Alvarez F, Bernard O, Homberg JC, Kreibich G. Anti-liverkidney microsome antibody recognizes a 50, 000 molecular weight protein of the endoplasmic reticulum. J Exp Med. 1985;161:1231-1236.
75. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Antiliver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med. 1988;168:801-806.
76. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 1989;83:1066-1072.
77. Obermayer-Straub P, Manns MP. Cytochrome P450 enzymes and UDP-glucuronosyltransferases as hepatocellular autoantigens. Mol Biol Rep. 1996;23:235-242. (Pubitemid 27153046)
78. Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med. 2002;13:293-303.
79. Bianchi FB, Muratori P, Muratori L. New autoantibodies and autoantigens in autoimmune hepatitis. Clin Liver Dis. 2002; 6:785-797.
80. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002;22:339-352.
81. Bogdanos DP, Dalekos GN. Enzymes as target antigens of liverspecific autoimmunity: the case of cytochromes P450s. Curr Med Chem. 2008;15:2285-2292.
82. Tahiri F, Le Naour F, Huguet S, et al. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology. 2008;47:937-948.
83. Song Q, Liu G, Hu S, et al. Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res. 2009.
84. Djilali-Saiah I, Lapierre P, Vittozi S, Alvarez F. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. J Immunol. 2002;169:4889-4896.
85. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology. 2004;39:1066-1074.
86. Lapierre P, Beland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun. 2006;26:82-89.
87. Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409-1422.
88. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250-259.
89. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci. 2002;47:2139-2150.
90. Brown JH, Jardetzky T, Saper MA, et al. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988;332:845-850.
91. Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol. 1998;161:3527-3535.
92. Corper AL, Stratmann T, Apostolopoulos V, et al. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science. 2000;288:505-511.
93. Penzotti JE, Doherty D, Lybrand TP, Nepom GT. A structural model for TCR recognition of the HLA class II shared epitope sequence implicated in susceptibility to rheumatoid arthritis. J Autoimmun. 1996;9:287-293.
94. Garboczi DN, Ghosh P, Utz U, et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 1996;384:134-141.
95. Friede T, Gnau V, Jung G, et al. Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochim Biophys Acta. 1996; 1316:85-101.
96. Volz T, Schwarz G, Fleckenstein B, et al. Determination of the peptide binding motif and high-affinity ligands for HLA-DQ4 using synthetic peptide libraries. Hum Immunol. 2004;65: 594-601.
97. Weyand CM, Hicok KC, Goronzy JJ. Nonrandom selection of T cell specificities in anti-HLA-DR responses. Sequence motifs of the responder HLA-DR allele influence T cell recruitment. J Immunol. 1991;147:70-78.
98. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028-2035.
99. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology. 1994;19:609-615.
100. Sakurai Y, Brand DD, Tang B, et al. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther. 2006;8:R150.
101. Myers LK, Tang B, Rosioniec EF, Stuart JM, Kang AH. An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol. 2007;27:345-356.
102. Myers LK, Sakurai Y, Tang B, et al. Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum. 2002;46:3369-3377.
103. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379-388.
104. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol. 1997;9:396-404.
105. Chambers CA. The expanding world of co-stimulation: the twosignal model revisited. Trends Immunol. 2001;22:217-223.
106. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 2001;410:604-608.
107. Viglietta V, Khoury SJ. Modulating co-stimulation. Neurotherapeutics. 2007;4:666-675.
108. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28- mediated costimulation. Immunol Rev. 2009;229:307-321.
109. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71:1065-1068.
110. Schwartz RS. The new immunology-the end of immunosuppressive drug therapy? N Engl J Med. 1999;340:1754-1756.
111. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143-155.
112. Weyand CM, Goronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2:201-210.
113. Ben-Shoshan M. CTLA-4Ig: uses and future directions. Recent Pat Inflamm Allergy Drug Discov. 2009;3:132-142.
114. Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-totreat juvenile idiopathic arthritis. Biologics. 2008;2:865-874.
115. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008;71:917-924.
116. de Jong YP, Rietdijk ST, Faubion WA, et al. Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis. Int Immunol. 2004;16: 205-213.
117. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther. 2007;7: 1245-1256.
118. Kallinich T, Beier KC, Gelfand EW, Kroczek RA, Hamelmann E. Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease. Clin Exp Allergy. 2005;35:1521-1534.
119. Vermeiren J, Ceuppens JL, Haegel-Kronenberger H, et al. Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity. Clin Exp Immunol. 2004;135:253-258.
120. Pham T, Claudepierre P, Constantin A, et al. Abatacept therapy and safety management. Joint Bone Spine. 2009;76(Suppl 1): S3-S55.
121. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995;16:34-38.
122. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532-562.
123. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224-1231.
124. Hopf U, Meyer zum Buschenfelde KH, Arnold W. Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med. 1976;294:578-582.
125. Gonzales C, Cochrane AM, Eddleston AL, Williams R. Mechanisms responsible for antibody-dependent, cell-mediated cytotoxicity to isolated hepatocytes in chronic active hepatitis. Gut. 1979;20:385-388.
126. Nouri-Aria KT, Hegarty JE, Alexander GJ, Eddleston AL, Williams R. IgG production in 'autoimmune' chronic active hepatitis. Effect of prednisolone on T and B lymphocyte function. Clin Exp Immunol. 1985;61:290-296.
127. Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver. 1987;7:307-315.
128. Czaja AJ. Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig Dis Sci. 1995;40:435-456.
129. McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother. 1999;53:255-263.
130. Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45: 1028-1035.
131. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727-737.
132. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology. 1996;23:909-916.
133. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int. 2006;26:1029-1039.
134. Cookson S, Constantini PK, Clare M, et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology. 1999;30:851-856.
135. Czaja AJ, Cookson S, Constantini PK, et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645-652.
136. Bittencourt PL, Palacios SA, Cancado EL, et al. Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308. J Hepatol. 2001; 35:24-28.
137. Tsikrikoni A, Kyriakou DS, Rigopoulou EI, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol. 2005;42:393-399.
138. Atzeni F, Sarzi-Puttini P,Doria A, IaccarinoL,Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev. 2005;4:144-152.
139. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993;11:165-190.
140. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994;179:1517-1527.
141. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:578-582.
142. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;CD007848.
143. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343-350.
144. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419-425.
145. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, doubleblinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135: 1953-1960.
146. Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-1371.
147. Ozorio G, McGarity B, Bak H, et al. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524-526.
148. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007; 26:578-581.
149. Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupuslike syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723-725.
150. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNFtargeted therapies. Best Pract Res Clin Rheumatol. 2008;22: 847-861.
151. Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol. 2009;34:421-422.
152. Licastro F, Chiappelli M, Ianni M, Porcellini E. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules. Int J Immunopathol Pharmacol. 2009;22:567-572.
153. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009;28:1001-1003.
154. Fuchs AC, Granowitz EV, Shapiro L, et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol. 1996;16:291-303.
155. Huhn RD, Radwanski E, O'Connell SM, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 1996;87:699-705.
156. Huhn RD, Radwanski E, Gallo J, et al. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther. 1997;62:171-180.
157. Rosenblum IY, Dayan AD. Carcinogenicity testing of IL-10: principles and practicalities. Hum Exp Toxicol. 2002;21:347-358.
158. Rosenblum IY, Johnson RC, Schmahai TJ. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol. 2002;35:56-71.
159. Skapenko A, Niedobitek GU, Kalden JR, Lipsky PE, Schulze- Koops H. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol. 2004;172:6427-6434.
160. Drazan KE, Wu L, Bullington D, Shaked A. Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg. 1996;31:411-414.
161. Thompson K, Maltby J, Fallowfield J, et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology. 1998;28:1597-1606.
162. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut. 1996;39:836-845.
163. McHutchison JG, Giannelli G, Nyberg L, et al. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res. 1999;19:1265-1270.
164. Nelson DR, Tu Z, Soldevila-Pico C, et al. Long-term interleukin therapy in chronic hepatitis C patients has a proviral and antiinflammatory effect. Hepatology. 2003;38:859-868.
165. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-1482.
166. Rachmawati H, Beljaars L, Reker-Smit C, et al. Pharmacokinetic and biodistribution profile of recombinant human interleukin- 10 following intravenous administration in rats with extensive liver fibrosis. Pharm Res. 2004;21:2072-2078.
167. Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab- responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008; 42:862-863.
168. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma. 2009;50:1083-1095.
169. Ilan Y. Oral tolerance: can we make it work? Hum Immunol. 2009;70:768-776.
170. Mizrahi M, Ilan Y. The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des. 2009;15:1191-1202.
171. Mowat AM. Basic mechanisms and clinical implications of oral tolerance. Curr Opin Gastroenterol. 1999;15:546-556.
172. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006;13:143-157.
173. Navarro MJ, Higgins GC, Lohr KM, Myers LK. Amelioration of relapsing polychondritis in a child treated with oral collagen. Am J Med Sci. 2002;324:101-103.
174. Cai Q, Du X, Zhou B, et al. Induction of tolerance by oral administration of beta-tubulin in an animal model ofautoimmune inner ear disease. ORL J Otorhinolaryngol Relat Spec. 2009;71:135-141.
175. Gonnella PA, Del Nido PJ, McGowan FX. Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice. J Clin Immunol. 2009;29:434-443.
176. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recentonset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006;116:1371-1381.
177. Broere F, Wieten L, Klein Koerkamp EI, et al. Oral or nasal antigen induces regulatory T cells that suppress arthritis and proliferation of arthritogenic T cells in joint draining lymph nodes. J Immunol. 2008;181:899-906.
178. Gumanovskaya ML, Myers LK, Rosloniec EF, Stuart JM, Kang AH. Intravenous tolerization with type II collagen induces interleukin-4-and interleukin-10-producing CD4+ T cells. Immunology. 1999;97:466-473.
179. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebocontrolled phase 1/2 trial. Arch Neurol. 2007;64:1407-1415.
180. Tutaj M, Szczepanik M. Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun. 2007;28:208-215.
181. Chatila TA. Molecular mechanisms of regulatory T-cell development. Chem Immunol Allergy. 2008;94:16-28.
182. Chen W, Perruche S, Li J. CD4+ CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245-2249.
183. Dubois B, Joubert G, Gomez de Aguero M, et al. Sequential role of plasmacytoid dendritic cells and regulatory T cells in oral tolerance. Gastroenterology. 2009;137:1019-1028.
184. Hanninen A, Harrison LC. Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans? Rev Diabet Stud. 2004;1:113-121.
185. Ishikawa H, Ochi H, Chen ML, et al. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 2007;56:2103-2109.
186. Ochi H, Abraham M, Ishikawa H, et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci. 2008;274:9-12.
187. Perruche S, Zhang P, Liu Y, et al. CD3-specific antibodyinduced immune tolerance involves transforming growth factorbeta from phagocytes digesting apoptotic T cells. Nat Med. 2008;14:528-535.
188. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63-71.
189. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484-4491.
190. Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31-37.
191. Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 2006;43:729-737.
192. Longhi MS, Mitry RR, Samyn M, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology. 2009;50:130-142.
193. Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581-591.
194. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2009.
195. Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: do "NK-reg cells" exist? Cell Mol Immunol. 2006;3:241-254.
196. Tupin E, Kronenberg M. Activation of natural killer T cells by glycolipids. Methods Enzymol. 2006;417:185-201.
197. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev Med Chem. 2006;6: 1249-1253.
198. Dennert G, Aswad F. The role of NKT cells in animal models of autoimmune hepatitis. Crit Rev Immunol. 2006;26:453-473. (Pubitemid 44785491)
199. Kawamura H, Aswad F, Minagawa M, Govindarajan S, Dennert G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J Immunol. 2006;176:2152-2160. (Pubitemid 43201662)
200. Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol. 2007;26:95-119.
201. Ma X, Qiu DK, Li EL, Peng YS, Chen XY. Effect of T-cell vaccination in murine experimental autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi. 2004;12:44-46.
202. Mei Y, Wang Y, Xu L. Suppression of immune-mediated liver injury after vaccination with attenuated pathogenic cells. Immunol Lett. 2007;110:29-35.
203. Little PF. Structure and function of the human genome. Genome Res. 2005;15:1759-1766.
204. Wolfsberg TG, McEntyre J, Schuler GD. Guide to the draft human genome. Nature. 2001;409:824-826.
205. Honda M, Kawai H, Shirota Y, et al. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J Autoimmun. 2005;25:133-140.
206. Schumacher A, Kapranov P, Kaminsky Z, et al. Microarraybased DNA methylation profiling: technology and applications. Nucleic Acids Res. 2006;34:528-542.
207. Yokosawa S, Yoshizawa K, Ota M, et al. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology. 2007;45:384-390.
208. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31: 49-53.
209. Hiraide A, Imazeki F, Yokosuka O, et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005;100:1322-1329.
210. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227-235.
211. Fan LY, Tu XQ, Zhu Y, et al. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol. 2005;11: 2768-2772. (Pubitemid 40704245)
212. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126-131.
213. Fan L, Tu X, Zhu Y, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005; 20:249-255. (Pubitemid 40343277)
214. Vogel A, Strassburg CP, Manns MP. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun. 2003;4:79-81.
215. Esteghamat F, Noorinayer B, Sanati MH, et al. C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis. Hepatol Res. 2005;32:154-157.
216. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805-809.
217. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321-1327.
218. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009; 51:156-160.
219. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25: 927-934.
220. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008;22:388-392.